Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

Bristol Myers Squibb announced positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel), its potential first-in-class GPRC5D-directed CAR T cell therapy, in quadruple-class exposed relapsed and refractory multiple myeloma. The trial met its primary endpoint of overall response rate and the key secondary endpoint of complete response rate in heavily pretreated patients who had received prior BCMA-targeted therapy, with a safety profile consistent with other CAR T cell therapies. No numeric response rates were disclosed; full results will be presented at an upcoming medical meeting.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.